@article {ZIMLING6731, author = {ZARAH GLAD ZIMLING and ERIC SANTONI-RUGIU and CECILIA BECH and JENS BENN S{\O}RENSEN}, title = {High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma}, volume = {35}, number = {12}, pages = {6731--6738}, year = {2015}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in non-small cell lung cancer (NSCLC) has been previously reported. The present study aimed to further explore this finding in malignant pleural mesothelioma (MPM). Materials and Methods: Seventy-one patients with MPM receiving first-line chemotherapy with cisplatin-vinorelbine (CiV group, n=54) or carboplatin-pemetrexed (CaP group, n=17) were included. Formalin-fixed paraffin-embedded tumor specimens were analyzed by immunohistochemistry (IHC) for RRM1 expression using an H-score. Results: In 66 patients eligible for IHC, the H-score was >=upper quartile in 21 (RRM1-positive) and \<upper quartile (RRM1-negative) in 45 cases. The long-term (2-year) survival rate for patients with RRM1-negative MPM in the CiV-treated group was significantly superior to that for patients with RRM1-positive MPM (47\% versus 13\%, p=0.002). No difference occurred in the CaP-treated group. Conclusion: Our findings suggest a possible role of RRM1 in predicting efficacy of cisplatin{\textendash}vinorelbine in MPM, supporting previous findings in NSCLC.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/35/12/6731}, eprint = {https://ar.iiarjournals.org/content/35/12/6731.full.pdf}, journal = {Anticancer Research} }